Knowledge-based diagnostic computer systems can be used to differentiate disease manifestations from adverse drug reactions (ADRs). Antiepileptic drugs (AEDs) are a frequent source of significant ADRs. Computer programs for the diagnosis of anticonvulsant ADRs must be proficient both in measuring common dose-dependent toxicity as well as warning about serious allergic or idiosyncratic reactions. The Clinical Ratings System from the Veterans Administration Cooperative Study (VACS) on the Efficacy and Toxicity of Antiepileptic Drugs was expanded to add coverage for valproic acid ADRs. A notebook computer system is utilized to administer the new VACS algorithm. This system is used to measure the balance between seizures and drug toxicity during an Epilepsy Clinic visit. This antiepileptic ADR diagnostic system will also be employed to determine the pattern, frequency, and prevalence of anticonvulsant ADRs in ambulatory adult epileptics.
ShortliffeEHPerreaultLEFaganLMWiederholdG, eds. The structure of medical data. In: Medical Informatics: Computer Applications in Health Care.Reading, MA: Addison-Wesley Publishing Company; 1990: 59–60.
2.
MillerRAPopleHEJrMyersJD. Internist-1, an experimental computer-based diagnostic consultant for general internal medicine. N Engl J Med.1982;307: 468–476.
3.
MillerRAMcNeilMAChallinorSMMasarieFEMyersJD. The Quick Medical Reference Project-status report. West J Med.1986;145: 816–822.
4.
BankowitzRAMcNeilMAChallinorSMParkerRCKapoorWNMillerRA. A computer-assisted medical diagnostic consultation service. Implementation and prospective evaluation of a prototype. Ann Intern Med.1989;110: 824–832.
5.
GoldbergAB. Foreword to the Third Edition. In: DaviesDM, ed. Textbook of Adverse Drug Reactions. Oxford, UK: Oxford University Press; 1985: vii–viii.
6.
JonesJK. Determining causation from case reports. In: StromBL, ed. Pharmacoepidemiology. New York: Churchill Livingstone; 1989: 276.
7.
NaranjoCABustoUSellersEMSandorPRuizIRobertsEAJanacekEDomecqCGreenblattDJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther.1981;30: 239–245.
8.
NaranjoCALanctotKL. Microcomputer-assisted Bayesian differential diagnosis of severe adverse reactions to new drugs: A 4-year experience. Drug Inf J.1991;25: 243–250.
9.
LaneDA. Causality assessment for adverse drug reactions. In: BerryDA, ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker; 1987: 475–508.
10.
LaneDA. Subjective probability and causality assessment. Applied Stochastic Models and Data Analysis.1989;5: 53–76.
11.
GiuseNBBankowitzRAGiuseDAParkerRCMillerRA. Medical knowledge base acquisition: The role of the expert review process in disease profile construction. In: Proceedings of the Thirteenth Annual Symposium on Computer Applications in Medical Care.Washington, DC: IEEE Computer Society Press; 1989: 105–109.
12.
MabryMEMillerRA. Distinguishing drug toxicity syndromes from medical diseases: A QMR computer-based approach. Computer Methods Programs Biomedicine.1991;35: 301–310.
13.
OldstoneMBNelsonE.Central nervous system manifestations of penicillin toxicity in man. Neurology.1966;16: 693–700.
14.
LaVineRBaudischR.Overview. In: Physicians' Desk Reference on CD-ROM. User's Guide.Montvale, NJ: Medical Economics Data; 1991: 1.
15.
JohnstonG.Drugs with Narrow Therapeutic Range of Low Therapeutic Index. Rockville, MD: Food and Drug Administration, Division of Generic Drugs, Center for Drug Evaluation Research; 1990.
16.
FilmyerJW. Leading epilepsy treatments. National Disease and Therapeutic Index. Plymouth Meeting, PA: IMS America; 1992.
17.
SanderJWShorvonSD. Incidence and prevalence studies in epilepsy and their methodological problems: A review. J Neurol Neurosurg Psychiatry.1987;50: 829–839.
18.
KurtzkeJF. Neuroepidemiology. Ann Neurol.1984;16: 265–277.
19.
National Institutes of Health Consensus Conference.Surgery for epilepsy. JAMA.1990;264: 729–733.
20.
SchmidtDEinickeIHaenelF.The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital, and carbamazepine. Arch Neurol.1986;43: 263–265.
21.
LeapeLLBrennanTALairdNThe nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice StudyU.N Engl J Med.1991;324: 377–384.
22.
ManasseHRJr.Medication use in an imperfect world: Drug misadventuring as an issue of public policy, Part 1. Am J Hosp Pharm.1989;46: 929–944.
Delgado-EscuitaAVMattsonRHSmithDBCramerJACollinsJH. Principles in designing clinical trials for antiepileptic drugs. Neurology.1983;33(Suppl 1):8–13.
25.
MattsonRHCramerJACollinsJFComparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med.1985;313: 145–151.
26.
MattsonRHCramerJAEscuetaDelgado AVA design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology.1983;33(Suppl 1):14–25.
27.
CramerJASmithDBMattsonRHA method of quantification for the evaluation of antiepileptic drug therapy. Neurology.1983;33(Suppl 1):26–37.
SmithDBMattsonRHCramerJACollinsJFNovellyRACraftB.Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia.1987;28(Suppl 3):S50–S58.
30.
PlaaGL. General Principles: Toxicology. In: LevyRHDreifussFEMattsonRHMeldrumBSPenryJK, eds. Antiepileptic Drugs. New York: Raven Press; 1989: 49–58.
31.
CamfieldPCamfieldCDooleyJFarrellKHumphreysPLangevinP.Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. Can Med Assoc J.1989;140: 1303–1305.
32.
CamfieldCCamfieldPSmithETibbiesJA. Asymptomatic children with epilepsy: Little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology.1986;36: 838–841.
33.
PellockJMWillmoreLJ. A rational guide to routine monitoring in patients receiving antiepileptic drugs. Neurology.1991;41: 961–964.
